Latest Ratios: P/E Ratio -24.2x · EV/EBITDA N/A · ROE 21.6%. (2006–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $464M | $1.0B | $1.4B | $1.3B | $314M | $667M | $983M | $811M | $189M | $1.5B | $998M |
| Enterprise Value | $320M | $870M | $1.4B | $1.2B | $300M | $633M | $939M | $811M | $144M | $1.4B | $964M |
| P/E Ratio → | -24.16 | 21.16 | 34.36 | 23.08 | — | — | — | — | — | 22.52 | 2531.43 |
| P/S Ratio | 1.53 | 2.42 | 4.11 | 3.98 | 1.17 | 2.75 | 3.96 | 2.71 | 0.53 | 4.56 | 4.07 |
| P/B Ratio | 1.86 | 3.95 | 7.43 | 8.97 | 4.21 | 7.20 | 10.75 | 23.57 | 3.81 | 19.84 | 7.50 |
| P/FCF | 22.76 | 13.89 | 22.23 | 51.64 | — | — | — | — | 7.17 | 25.33 | 56.57 |
| P/OCF | 6.26 | 13.70 | 21.66 | 47.81 | — | — | — | — | 5.28 | 23.26 | 41.85 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.08 | 3.88 | 3.88 | 1.12 | 2.61 | 3.78 | 2.71 | 0.40 | 4.47 | 3.93 |
| EV / EBITDA | — | 11.05 | 20.87 | 30.74 | — | — | — | — | 48.17 | 27.64 | 151.67 |
| EV / EBIT | 5.01 | 12.79 | 22.83 | 33.60 | — | — | — | — | 13.50 | 30.70 | 278.76 |
| EV / FCF | — | 11.92 | 20.99 | 50.27 | — | — | — | — | 5.46 | 24.86 | 54.62 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.6% | 82.6% | 82.8% | 83.0% | 82.0% | 83.6% | 84.2% | 85.6% | 89.9% | 89.0% | 86.8% |
| Operating Margin | 15.3% | 15.3% | 16.9% | 11.5% | -5.5% | -2.9% | -18.3% | -7.1% | -1.1% | 14.4% | 0.4% |
| Net Profit Margin | 11.6% | 11.6% | 12.2% | 21.0% | -11.3% | -5.1% | -19.9% | -8.5% | -8.3% | 20.2% | 4.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 21.6% | 21.6% | 25.3% | 62.1% | -36.1% | -13.4% | -78.3% | -60.9% | -48.6% | 62.6% | 9.9% |
| ROA | 16.0% | 16.0% | 16.9% | 32.9% | -16.8% | -6.3% | -26.7% | -17.6% | -24.6% | 41.2% | 7.3% |
| ROIC | 42.3% | 42.3% | 39.7% | 32.8% | -18.4% | -10.0% | -82.5% | -79.7% | -11.5% | 47.7% | 0.7% |
| ROCE | 25.7% | 25.7% | 28.6% | 23.1% | -10.8% | -4.9% | -37.4% | -28.0% | -6.2% | 42.4% | 0.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.13 | 0.34 | 0.70 | 0.58 | 0.57 | 2.03 | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | 0.29 | 0.29 | 0.38 | 1.19 | — | — | — | — | 0.08 | 0.01 | 0.00 |
| Net Debt / Equity | — | -0.56 | -0.41 | -0.24 | -0.18 | -0.36 | -0.48 | 0.02 | -0.90 | -0.37 | -0.26 |
| Net Debt / EBITDA | -1.82 | -1.82 | -1.23 | -0.84 | — | — | — | — | -15.00 | -0.52 | -5.41 |
| Debt / FCF | — | -1.97 | -1.23 | -1.37 | — | — | — | — | -1.70 | -0.47 | -1.95 |
| Interest Coverage | 38.16 | 38.16 | 58.96 | 5.74 | -2.94 | -1.42 | -5.59 | -4.40 | — | 538.08 | 10.20 |
Net cash position: cash ($166M) exceeds total debt ($23M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.32 | 4.32 | 4.21 | 3.57 | 3.08 | 3.51 | 2.71 | 1.83 | 1.03 | 1.06 | 2.49 |
| Quick Ratio | 3.92 | 3.92 | 3.69 | 3.11 | 2.78 | 3.24 | 2.54 | 1.70 | 0.81 | 0.86 | 2.14 |
| Cash Ratio | 2.58 | 2.58 | 2.29 | 1.78 | 1.51 | 2.06 | 1.62 | 1.03 | 0.63 | 0.60 | 0.68 |
| Asset Turnover | — | 1.22 | 1.32 | 1.34 | 1.56 | 1.29 | 1.23 | 1.79 | 2.92 | 2.65 | 1.27 |
| Inventory Turnover | 2.88 | 2.88 | 2.52 | 2.60 | 3.67 | 3.48 | 3.80 | 4.73 | 2.28 | 3.72 | 1.82 |
| Days Sales Outstanding | — | 66.01 | 58.41 | 61.16 | 58.71 | 60.86 | 52.09 | 39.43 | 0.46 | 0.75 | 100.04 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | 4.7% | 2.9% | 4.3% | — | — | — | — | — | 4.4% | 0.0% |
| FCF Yield | 4.4% | 7.2% | 4.5% | 1.9% | — | — | — | — | 14.0% | 3.9% | 1.8% |
| Buyback Yield | 0.7% | 0.3% | 0.2% | 0.7% | 0.4% | 0.7% | 0.2% | 0.2% | 6.6% | 4.9% | 1.2% |
| Total Shareholder Yield | 0.7% | 0.3% | 0.2% | 0.7% | 0.4% | 0.7% | 0.2% | 0.2% | 6.6% | 4.9% | 1.2% |
| Shares Outstanding | — | $150M | $149M | $146M | $113M | $110M | $108M | $107M | $106M | $116M | $113M |
Includes 30+ ratios · 20 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MDXG stock.
MiMedx Group, Inc.'s current P/E ratio is -24.2x. The historical average is 27.4x.
MiMedx Group, Inc.'s return on equity (ROE) is 21.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -41.0%.
Based on historical data, MiMedx Group, Inc. is trading at a P/E of -24.2x. Compare with industry peers and growth rates for a complete picture.
MiMedx Group, Inc. has 82.6% gross margin and 15.3% operating margin. Operating margin between 10-20% is typical for established companies.
MiMedx Group, Inc.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Revenue reversal and reimbursement exposure
Metrics are mathematically derived from official filings.
Negative Earnings Leave Multiples Uninformative
Based on MDXG's reported figures, the trailing P/E of -25.23 is not meaningful, leaving P/S of 1.59 and P/FCF of 23.77 as the more usable anchors for a company posting losses and volatile free cash flow.
With earnings negative, the P/E cannot be interpreted against history or peers, and forward P/E and EV/EBITDA are unavailable in the supplied data, so valuation rests on sales and cash flow multiples. The P/FCF of 23.77 appears reasonable only if the recent 8.3% free cash flow margin proves durable, which the volatile 2026 path does not yet confirm. Investors should monitor whether a sustained return to positive operating cash flow supports the current multiple.
Gross Margin Holds While Operating Margin Collapses
Reported gross margin of 79.8% in 2026Q3 remains near the 81% to 84% range of 2025, yet operating margin fell from 19.5% in 2025Q3 to a negative 18.8% in the latest quarter, according to reported quarterly figures.
The stable gross margin suggests the product economics of the EpiFix franchise remain intact, which points the deterioration toward operating cost absorption rather than pricing. SG&A of roughly $58M to $60M per quarter against a revenue base that nearly halved implies substantial operating leverage working in reverse. The pattern suggests the earnings base is highly sensitive to volume, warranting caution in extrapolating any single quarter.
Returns Swing From Compounding to Erosion
As reported in financial statements, MDXG's ROIC moved from 14.4% in 2025Q3 to negative 15.2% in 2026Q2 and negative 10.2% in 2026Q3, a reversal that tracks the margin collapse rather than capital intensity.
Return on capital decayed quickly because the capital base stayed substantial while earnings turned negative, so the driver appears to be margins rather than asset efficiency. ROE of negative 4.1% and ROA of negative 3.2% in the latest quarter indicate the equity and asset base are not currently generating returns. The durability of the prior 2025 returns is therefore the central question for assessing whether the business compounds again.
Working Capital Lengthens Cash Conversion Cycle
Based on MDXG's reported figures, the cash conversion cycle expanded from 122 days in 2025Q4 to 142 days in 2026Q3, driven primarily by DIO rising from 125 to 157 days while DSO held near 58 to 62 days.
The lengthening inventory days, combined with DPO that compressed from 63 to 74 days in the wrong direction for the cycle, suggests inventory is building faster than sales are recovering. Asset turnover fell to 0.23 from 0.36, indicating the asset base is no longer generating revenue efficiently. Investors should monitor whether inventory write-down risk emerges if the revenue recovery does not materialize.
Liquidity Remains Strong Despite Cash Decline
Reported current ratio of 4.35 and quick ratio of 3.84 in 2026Q3, against a current ratio of 4.32 in 2025Q4, indicate MDXG retains a considerable short-term buffer even as cash fell from $166.1M to $120.8M.
The near-identical quick and current ratios imply that liquid assets, mainly cash and receivables, dominate current assets, so inventory dependence is limited. Under a severe stress scenario, the reported cash balance alone would appear to cover current liabilities several times over. The more relevant question is the pace of cash burn if operating losses persist at the 2026 run rate.
Medicare Reimbursement Could Compress Net Pricing
Based on MDXG's reported figures, the 2026 revenue decline and margin compression may reflect reimbursement exposure rather than a temporary timing effect, though the supplied data cannot confirm the cause.
The most commonly misapplied metric for this business is gross margin, since a stable 79.8% headline figure can mask net ASP erosion from payer policy changes that do not yet appear in cost of goods. Measuring net revenue per unit and site-of-service mix would better isolate pricing pressure than the headline gross margin. Investors should monitor Medicare administrative contractor rulemaking on skin substitute applications before concluding that the 2026 volume reversal is structural.